About
Team
Pipeline
Newsroom
Careers
Newsroom
Digital screen with DNA data background. Nucleic acid sequence. Genetic research. 3d illustration.
Search
May 2, 2023
Kriya to Present 10 Abstracts at the 2023 American Society of Gene and Cell Therapy Annual Meeting
: Kriya to Present 10 Abstracts at the 2023 American Society of Gene and Cell Therapy Annual Meeting
November 16, 2022
Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio
: Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio
August 25, 2022
Kriya Appoints Curt Herberts as President and Chief Operating Officer
: Kriya Appoints Curt Herberts as President and Chief Operating Officer
May 16, 2022
Kriya Announces $270 Million Series C Financing to Advance Fully Integrated Gene Therapy Engine
: Kriya Announces $270 Million Series C Financing to Advance Fully Integrated Gene Therapy Engine
January 26, 2022
Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases
: Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases
July 28, 2021
Kriya Therapeutics Completes Renovation of its Facility for Scalable Gene Therapy Manufacturing
: Kriya Therapeutics Completes Renovation of its Facility for Scalable Gene Therapy Manufacturing
July 14, 2021
Kriya Therapeutics Completes $100 Million Series B Financing to Advance its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies
: Kriya Therapeutics Completes $100 Million Series B Financing to Advance its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies
August 4, 2020
Kriya Therapeutics Announces the Establishment of its Internal Manufacturing Facility for Process Development and Scalable cGMP Production of Gene Therapies for Prevalent Serious Diseases
: Kriya Therapeutics Announces the Establishment of its Internal Manufacturing Facility for Process Development and Scalable cGMP Production of Gene Therapies for Prevalent Serious Diseases
May 12, 2020
Kriya Therapeutics Announces $80 Million Series A Financing to Advance Gene Therapies for Highly Prevalent Serious Diseases
: Kriya Therapeutics Announces $80 Million Series A Financing to Advance Gene Therapies for Highly Prevalent Serious Diseases
Media Contacts
Kriya Therapeutics, Inc.
[email protected]
833-574-9289
